The Problem With How GLP-1 Is Being Used Right Now
GLP-1 therapies, including household names like Mounjaro, have become the most talked-about class of medications in the world. Demand in the UAE is surging. However, demand and clinical safety are not the same thing. Across the Gulf, patients are accessing these powerful metabolic drugs without adequate medical supervision, nutritional support, or long-term follow-up plans. That is the gap that Hoopoe Holding is stepping in to close.
What Hoopoe Holding Is Actually Building
Shahriar Shahir Barzegar, Founder of Hoopoe Holding, has formally launched a standardized clinical framework for GLP-1 therapy delivery across the UAE. This framework is structured, supervised, and designed to produce measurable outcomes. "The market is moving quickly toward broader access," said Barzegar. "What we are introducing is a structured clinical layer to ensure that this access translates into safe, measurable, and sustainable outcomes."
Three Clinical Pillars
The framework does not simply prescribe and step back. It is built on three core objectives that address the most common failure points in weight-loss treatment: Metabolic Profiling: Selecting the right patients based on individual hormonal and metabolic data, rather than using a one-size-fits-all prescription. Muscle Mass Preservation: GLP-1 drugs can cause lean mass loss during rapid weight reduction. The framework employs specific strength and nutritional protocols to protect muscle. Weight Stability Post-Treatment: Long-term maintenance protocols are set in place to prevent weight regain, which is the phase where most programs currently fail their patients.
The Hayat Initiative: Reframing Obesity as a Medical Condition
The framework is being deployed alongside the Hayat Initiative, a UAE-wide awareness campaign developed with Eli Lilly and TruBody USA. The core message is that obesity is not a lifestyle failure; it is a chronic metabolic condition that requires clinical intervention, not willpower alone. This reframing is crucial for how the healthcare system, insurers, and employers across the GCC perceive metabolic health support.
How Patients Will Access the System
As oral GLP-1 medications come to market, which is expected to broaden access significantly, Hoopoe Holding is expanding its licensed infrastructure to ensure patient supervision keeps pace with availability.
